Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Greater China Junior Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Julius Wong who wrote (654)	4/15/2004 5:35:47 AM
From: brianmargolis	Read Replies (1) \| Respond to of 1992

Tiens Biotech (TGBU), a developer, mfr and distributor of healthcare products in China, yesterday announced resuts which on the surface seem impressive: Reports Consolidated Net Income Increased by 754.4% for 2003 The company reported that its consolidated net income increased by $15,057,957, or approximately 754.4%, from $1,995,865 for the year ended December 31, 2002 to $17,053,822 for the year ended December 31, 2003. As of December 31, 2003, the company had $20,453,290 of retained earnings, cash of $12,725,043 and total shareholders' equity of $33,086,192. For the year ended December 31, 2003, it had revenues of $38,392,208 and general, administrative and sales expenses of $3,171,338. Shares dipped on the results. Is anyone following this company? Should we?